Skip to content

a Multicentre real world study and pharmacoeconomic analysis of Roxadustat in the treatment of anemia in CKD

a Multicentre real world study and pharmacoeconomic analysis of Roxadustat in the treatment of anemia in CKD

Status
Recruiting
Phases
Phase 4
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2100044135
Enrollment
Unknown
Registered
2021-03-11
Start date
2021-04-01
Completion date
Unknown
Last updated
2021-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

anemia in patients with chronic kidney disease receiving or not-receiving dialysis

Interventions

Sponsors

Shenzhen People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Aged >= 18 years. 2. Consistent with the diagnosis of renal anemia. 3. Voluntary Informed Consent (ICF). 4. Baseline alanine aminotransferase or aspartate aminotransferase (AST) <= 3 x ULN, total bilirubin (TBL) <= 2 x ULN.

Exclusion criteria

Exclusion criteria: 1. Patients with severe liver disease. 2. Women who are pregnant or breastfeeding, women of reproductive age who do not use adequate contraceptives or men whose sexual partners are women of reproductive age. 3. Mental disorders can not cooperate with treatment.

Design outcomes

Primary

MeasureTime frame
The Hb level;Costs due to adverse drug events every month;Blood biochemical index;

Secondary

MeasureTime frame
The rate of increase in HB;he proportion of patients with Hb >=10 g/dL;reticulocyte;the dose of Roxadustat used;blood pressure;Iron metabolism;Cholesterol;adverse event;Roxadustat charges every month;cost of blood tests every month;

Countries

China

Contacts

Public ContactZhang Xinzhou

Shenzhen People's Hospital

echobbg@163.com+86 13622379939

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026